Dr. Reddy's Laboratories moves up as its Aurigene inaugurates biologics facility in Hyderabad

Dr. Reddy's Laboratories is currently trading at Rs. 5810.25, up by 26.40 points or 0.76% from its previous closing of Rs. 5783.85 on the BSE.

The scrip opened at Rs. 5800.05 and has touched a high and low of Rs. 5827.95 and Rs. 5712.05 respectively. So far 3370 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 6505.50 on 28-Feb-2024 and a 52 week low of Rs. 4570.05 on 06-Jun-2023.

Last one week high and low of the scrip stood at Rs. 6015.00 and Rs. 5757.45 respectively. The current market cap of the company is Rs. 96488.71 crore.

The promoters holding in the company stood at 26.65%, while Institutions and Non-Institutions held 47.44% and 10.55% respectively.

Aurigene Pharmaceutical Services (Aurigene), a Dr. Reddy’s Laboratories company, has inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with process & analytical development and small scale manufacturing of antibodies and other recombinant proteins for preclinical and early phase clinical requirements. The process and analytical development laboratories are now operational while the commissioning of manufacturing capacity will be completed later in 2024.

The state-of-the-art facility is equipped with best-in-class equipment and control systems, supported by an experienced talent pool that will ensure seamless transfer to large-scale commercial CGMP manufacturing facilities. The new facility is complementary to the company’s current discovery capabilities and infrastructure, which primarily focuses on recombinant proteins including mAbs, bi- and multi-specifics, immune-fusion molecules, antibody drug conjugates and other complex proteins.

Aurigene’s comprehensive end-to-end service offering now delivers solutions from, discovery through large-scale commercial manufacturing from three proximally located campuses (discovery, process development/clinical manufacture and large scale commercial manufacture) thus ensuring seamless delivery from ‘concept to commercial’. The newly opened Genome Valley facility will deliver robust, compliant and economically viable cell lines, process development solutions and supporting analytical methods in support of customers seeking to rapidly enter and progress through clinical development.

Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.